Seymour J F, Gagel R F, Hagemeister F B, Dimopoulos M A, Cabanillas F
Royal Melbourne Hospital, Victoria, Australia.
Ann Intern Med. 1994 Nov 1;121(9):633-40. doi: 10.7326/0003-4819-121-9-199411010-00001.
To determine the following: a reference range for serum calcitriol during hypercalcemia in a control group of patients with myeloma in whom calcitriol production is known to be appropriately suppressed; the incidence of elevated serum calcitriol levels in hypercalcemic patients with non-Hodgkin lymphoma according to this derived reference range; and the incidence of abnormal calcium metabolism in normocalcemic patients with non-Hodgkin lymphoma.
Prospective clinical study.
Referral cancer center.
2 groups of hypercalcemic patients: 16 control patients with myeloma and 22 patients with non-Hodgkin lymphoma divided into those with elevated or normal serum calcitriol levels; 1 group of 22 normocalcemic patients with non-Hodgkin lymphoma.
Serum chemistries and intact parathyroid hormone, calcitriol, parathyroid hormone-related protein, and urinary electrolyte levels.
On the basis of the mean serum calcitriol level of the control group plus 3 standard deviations, the reference range for serum calcitriol during hypercalcemia was defined as less than 42 pg/mL. Although serum calcium and parathyroid hormone levels in the study patients were similar to those in controls, 12 of the 22 hypercalcemic patients with non-Hodgkin lymphoma (55%) had serum calcitriol levels greater than 42 pg/mL (range, 51 to 170 pg/mL). No features distinguished the patients with elevated serum calcitriol levels from those with normal levels. Seventy-one percent of normocalcemic patients with non-Hodgkin lymphoma were hypercalciuric, and 18% had serum calcitriol levels greater than the normocalcemic reference range (20 to 76 pg/mL).
Serum calcitriol levels are elevated in most hypercalcemic patients with non-Hodgkin lymphoma in the absence of elevated serum levels of parathyroid hormone, which implicates extrarenal calcitriol production in the pathogenesis of this syndrome. Abnormal calcium metabolism, hypercalciuria, and dysregulated calcitriol production are also common in normocalcemic patients with non-Hodgkin lymphoma.
确定以下内容:已知骨化三醇生成受到适当抑制的骨髓瘤对照组患者高钙血症期间血清骨化三醇的参考范围;根据此推导的参考范围,非霍奇金淋巴瘤高钙血症患者血清骨化三醇水平升高的发生率;以及非霍奇金淋巴瘤血钙正常患者钙代谢异常的发生率。
前瞻性临床研究。
转诊癌症中心。
2组高钙血症患者:16例骨髓瘤对照患者和22例非霍奇金淋巴瘤患者,后者又分为血清骨化三醇水平升高或正常的患者;1组22例非霍奇金淋巴瘤血钙正常患者。
血清化学指标、完整甲状旁腺激素、骨化三醇、甲状旁腺激素相关蛋白及尿电解质水平。
根据对照组血清骨化三醇水平均值加3个标准差,高钙血症期间血清骨化三醇的参考范围定义为低于42 pg/mL。尽管研究患者的血清钙和甲状旁腺激素水平与对照组相似,但22例非霍奇金淋巴瘤高钙血症患者中有12例(55%)血清骨化三醇水平高于42 pg/mL(范围为51至170 pg/mL)。血清骨化三醇水平升高的患者与正常水平的患者之间无明显特征差异。71%的非霍奇金淋巴瘤血钙正常患者有高钙尿症,18%的患者血清骨化三醇水平高于血钙正常参考范围(20至76 pg/mL)。
大多数非霍奇金淋巴瘤高钙血症患者在血清甲状旁腺激素水平未升高的情况下血清骨化三醇水平升高,这表明该综合征的发病机制与肾外骨化三醇生成有关。非霍奇金淋巴瘤血钙正常患者中钙代谢异常、高钙尿症及骨化三醇生成失调也很常见。